Myelodysplastic and myeloproliferative disorders in children

Current Opinion in Pediatrics

Volumn 19, Issue 1, 2007, Pages 1-8

  Hasle, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Juvenile myelomonocytic leukemia; Myelodysplastic syndrome; Myeloid leukemia of Down syndrome

Indexed keywords

AMIFOSTINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; HORMONE; MELPHALAN; PURINE DERIVATIVE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN SYNDROME; GENE MUTATION; HEALTH CARE ORGANIZATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REVIEW; STEM CELL TRANSPLANTATION; T CELL DEPLETION; WHOLE BODY RADIATION;

CHILD; DIAGNOSIS, DIFFERENTIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; TRANSPLANTATION CONDITIONING;

EID: 33846266236     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3280128ce8     Document Type: Review

References (69)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-625.
2. Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17:277-282.
4. Steliarova-Foucher E, Stiller C, Lacour B, et al. International Classification of Childhood Cancer, third edition. Cancer 2005; 103:1457-1467. The first classification of childhood malignancy to incorporate MDS and JMML.
5. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102:1997-2003.
6. Mandel K, Dror Y, Poon A, et al. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC System. J Pediatr Hematol Oncol 2002; 24:596-605.
7. Occhipinti E, Correa H, Yu L, et al. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders. Pediatr Blood Cancer 2005; 44:240-244. This article compares the pediatric WHO and CCC classification systems.
8. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355:165-169.
9. Hellebostad M, Carpenter E, Hasle H, et al. GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis. J Pediatr Hematol Oncol 2005; 27:408-409. One Down syndrome patient with ML-DS and 4 years later with acute lymphoblastic leukemia. Molecular studies suggest distinct pathogenetic events involved in the two leukemias.
10. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128:797-804. A large population-based epidemiologic and clinical study on ML-DS and acute lymphoblastic leukemia in Down syndrome.
11. Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 2005; 44:40-44. A review of the fascinating advances in molecular biology of ML-DS.
12. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5:11-20. A comprehensive review of leukemias in Down syndrome.
13. Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006; 103:3339-3344. The study identifies distinct gene-expression signatures for ML-DS.
14. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19:1355-1360. This reports on the German AML-BFM 93 study showing survival in ML-DS of 93% despite a reduction in therapy compared to non-Down syndrome.
15. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132:576-583. This paper reports on UK data showing a high risk of treatment-related death and a low risk of relapse with improving event-free survival in the AML 12 trial to 83%.
16. Webb DK. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131:3-7. Review of the literature and present UK data on therapy, treatment-related death and survival
17. Abildgaard L, Ellebæk E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85:275-280. Nordic data and a literature review demonstrating that both a reduction in treatment dose and a less intensively timed treatment regimen improve the outcome.
18. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19:2101-2116. A review of the Pediatric Oncology Group studies showing very favorable outcome in ML-DS.
19. Al Ahmari A, Shah N, Sung L, et al. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol 2006; 133:646-648. Very low-dose chemotherapy gave 77% 5-year survival in ML-DS.
20. Ge Y, Dombkowski AA, Lafiura KM, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006; 107:1570-1581. Distinct gene expression in ML-DS correlates with chemosensitivity.
21. Passmore SJ, Chessells JM, Kempski H, et al. Paediatric MDS and JMML in the UK: a population based study of incidence and survival. Br J Haematol 2003; 121:758-767.
22. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999; 93:459-466.
23. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001; 15:1713-1720.
24. Hasle H, Wadsworth LD, Massing BG, et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106:1027-1032.
25. Ortmann CA, Niemeyer CM, Wawer A, et al. TERC mutations in children with refractory cytopenia. Haematologica 2006; 91:707-708. Screening of 80 children with hypoplastic refractory cytopenia and normal karyotype detected TERC mutation in two patients without physical signs of dyskeratosis congenita.
26. Field JJ, Mason PJ, An P, et al. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol 2006; 28:450-453.
27. Jekic B, Novakovic I, Lukovic L, et al. Low frequency of NRAS and KRAS2 gene mutations in childhood myelodysplastic syndromes. Cancer Genet Cytogenet 2004; 154:180-182.
28. Vidal DO, Paixao VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2006 [epub ahead of print]. Aberrant methylation was a frequent finding in 21 children with MDS suggesting that treatment with demethylating agents may be effective.
29. Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol 2005; 128:805-812. The frequency of p15 hypermethylation in pediatric MDS was 78%, comparable with that in adult MDS; in contrast, p15 hypermethylation was rare in JMML (17%).
30. Kratz CP, Rogge T, Kopp M, et al. Myelodysplastic features in an infant with cystic fibrosis presenting with anaemia, oedema and failure to thrive. Eur J Pediatr 2005; 164:56-57.
31. Haimi M, Elhasid R, Gershoni-Baruch R, et al. Myeloid dysplasia in familial 3-methylglutaconic aciduria. J Pediatr Hematol Oncol 2006; 28:69-72.
32. Knerr I, Metzler M, Niemeyer CM, et al. Hematologic features and clinical course of an infant with Pearson syndrome caused by a novel deletion of mitochondrial DNA. J Pediatr Hematol Oncol 2003; 25:948-951.
33. Cantù-Rajnoldi A, Fenu S, Kerndrup G, et al. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84:429-433. The morphology group of the EWOG-MDS set the definitions for myelodysplasia and comparing interobserver variation.
34. Goyal R, Varma N, Marwaha RK. Myelodysplastic syndrome with erythroid hypoplasia. J Clin Pathol 2005; 58:320-321.
35. Webb DKH, Passmore SJ, Hann IM, et al. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain. Br J Haematol 2002; 117:33-39.
36. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002; 20:434-440.
37. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myelodysplastic syndromes proliferative disease. Blood 2005; 105:2183-2185. The spectrum of PTPN11 mutations differed between patients with JMML, patients with Noonan syndrome/MPD and patients with Noonan syndrome, suggesting a strong genotype-phenotype correlation.
38. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer 2006; 46:579-585. A comprehensive review of germline and somatic mutations in the Ras signaling pathway in JMML.
39. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra®) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group Study (ASH Annual Meeting Abstracts). Blood 2005; 106: abstract 2587.
40. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38:331-336. The fascinating story of how knowledge of somatic Ras mutations in JMML led to the search for and identification of germline Ras mutations causing some cases of Noonan syndrome.
41. Reimann C, Arola M, Bierings M, et al. A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukemia 2006; 20:1637-1638.
42. Hasle H, Baumann I, Bergsträsser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18:2008-2014.
43. Steensma DP, Dispenzieri A, More SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101:2156-2158.
44. Stary J, Locatelli F, Niemeyer CM. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant 2005; 35 (Suppl 1):S13-S16.
45. Yusuf U, Frangoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004; 33:805-814.
46. Trobaugh-Lotrario AD, Kletzel M, Quinones RR, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 2005; 35:143-149.
47. Copelan EA, Penza SL, Elder PJ, et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 2000; 25:1219-1222.
48. Kalwak K, Wojcik D, Gorczynska E, et al. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative? Transplant Proc 2004; 36:1574-1577.
49. Bader P, Niemeyer C, Willasch A, et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by preemptive immunotherapy. Br J Haematol 2005; 128:649-658. Preemptive immunotherapy in patients showing increasing mixed chimerism improved event-free survival from 0%, seen in prior studies, to 50%.
50. Bader P, Niemeyer C, Weber G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 2004; 73:25-28.
51. Tamura K, Kanazawa T, Suzuki M, et al. Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome. Am J Hematol 2006; 81:139-141.
52. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18:963-971.
53. Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002; 100:427-434.
54. Tsurusawa M, Manabe A, Hayashi Y, et al. Therapy-related myelodysplastic syndrome in childhood: a retrospective study of 36 patients in Japan. Leuk Res 2005; 29:625-632. A retrospective study of 36 children with therapy-related MDS. Chromosomal abnormalities were detected in 94%. The 5-year survival was only 16%.
55. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107:4628-4635. In a cohort of 374 patients with severe congenital neutropenia and 29 patients with Shwachman-Diamond syndrome on long-term granulocyte colony-stimulating factor therapy the cumulative incidence of myeloid leukemia was 21% after 10 years. A subgroup of patients with severe congenital neutropenia (29%) receiving more than the median dose of granulocyte colony-stimulating factor had a 40% risk of MDS/AML. In less-responsive severe congenital neutropenia patients, early HSCT seems to be the treatment of choice.
56. Cesaro S, Oneto R, Messina C, et al. Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. Br J Haematol 2005; 131:231-236. A European Group for Blood and Marrow Transplantation (EBMT) study on 26 patients receiving HSCT for Shwachman syndrome demonstrated an overall survival of 65%.
57. Niemeyer CM, Aricò M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997; 89:3534-3543.
58. Hasle H, Kerndrup G, Yssing M, et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996; 10:1269-1273.
59. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone Marrow Transplant 1996; 18:1111-1116.
60. Shimada H, Shima H, Shimasaki N, et al. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol 2005; 16:1400.
61. Corey SJ, Elopre M, Weitman S, et al. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 2005; 27:166-168.
62. Bergstraesser E, Hasle H, Rogge T, et al. Nonhematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2006 [epub ahead of print]. A detailed evaluation of 129 non-HSCT treatment courses in 63 children with JMML. Response was evaluated separately for hepato- and splenomegaly as well as white-cell and platelet count. The response in white-cell count correlated with splenomegaly but not with hepatomegaly or platelet count.
63. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16:645-649.
64. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002; 116:716-724.
65. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105:410-419. The hitherto largest series (n 1/4 100) of transplanted JMML patients. All patients received busulfan, cyclophosphamide and melphalan resulting in overall survival at 5 years of 64%. Disease recurrence was the major cause of treatment failure.
66. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566-573.
67. Yoshimi A, Niemeyer CM, Bohmer V, et al. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2005; 129:542-549. Serial quantitative chimerism studies of peripheral blood identified patients at high risk for relapse of JMML.
68. Yoshimi A, Bader P, Matthes-Martin S, et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19:971-977. A study of 21 patients receiving donor leukocyte infusion following HSCT. The overall outcome was poor even for the responders.
69. Faraci M, Micalizzi C, Lanino E, et al. Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia. Pediatr Transplant 2005; 9:797-800.